From Nature Cover to Human Trial: The First Clinical Test for "Reversing Aging" Therapy Finally Begins
Release time:
2026-04-13
The "reversing aging" study that graced the cover of Nature six years ago has finally left the lab and entered human trials. A "partial reprogramming" gene therapy, co-developed by Yuancheng Lu, a former Chinese doctoral student in David Sinclair's lab at Harvard Medical School, has recently received FDA approval to launch the world's first human clinical trial targeting cellular aging reversal. This marks the first time the once sci-fi concept of "rejuvenation" will be scientifically tested in humans.
From Failure to Cover: A Reversal Under the Microscope
The story traces back to an afternoon several years ago. In a Harvard lab, Yuancheng Lu, then a Ph.D. student, held his breath and stared into the microscope — he was attempting to rewind the clock on aging retinal neurons. After three years of failure, this time the neurons showed clear signs of rejuvenation. This "partial reprogramming" technique, using three factors — Oct4, Sox2, and Klf4 (collectively OSK) — successfully reversed vision loss in aged mice and in a mouse model of glaucoma.
Published in 2016 and featured on the cover of Nature, the breakthrough caused a sensation. Unlike the four factors (OSKM) used by Shinya Yamanaka, the father of induced pluripotent stem cells (iPSCs), Sinclair's team boldly omitted the cancer risk-associated c-Myc factor, retaining only three factors. This avoided the risk of cancer while achieving rejuvenation of tissue function.
Capital Frenzy and the First Human Injection
This foundational research has now borne commercial fruit. Life Biosciences, a company founded by David Sinclair, received FDA approval for its OSK therapy (code-named ER-100) in January of this year. Recently, the first subject has completed an eye injection.
Because the FDA does not recognize "aging" itself as a disease, the trial cleverly targets two age-related blinding diseases: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The trial will recruit no more than 18 patients. A modified viral vector delivers the OSK genes to the affected eye, and a genetic switch ensures the therapy is active only when the patient takes a specific antibiotic, thereby ensuring long-term safety.
A Milestone in Redefining Aging
From Shinya Yamanaka's Nobel Prize-winning discovery of iPSCs at Kyoto University to today's OSK therapy entering human trials, humanity is making tangible strides in the fight against aging. Industry experts believe that regardless of the trial's outcome, it represents the first attempt to physiologically reverse organ aging in humans. As Yuancheng Lu said, advancing a fundamental research discovery to clinical treatment is an exceptionally rare achievement in a scientific career.
In the future, whether this technology can "rejuvenate" the kidneys, liver, and even the brain is worth continued attention.
Latest developments
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
The significance of life extension lies not only in technological breakthroughs but also in the shared belief of every individual who believes in "a better future." With faith as their torch, these fellow travelers join hands, pooling their strength to stride forward together. We firmly believe that as this steadfast support converges into a powerful force, it will propel the Yinfeng Life Extension Plan to gain broader attention, inject continuous momentum into the development of cryobiomedicine, and illuminate the next chapter of human civilization.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
